share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股SEC公告 ·  12/17 06:03

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
Conduit Pharmaceuticals Inc. 向 A.G.P./Alliance Global Partners 發行了一張 5,737,500 美元的可轉換票據，到期日爲 2025 年 11 月 25 日。該票據按年利率 5.5% 計息，並可按每股 0.10 美元的價格轉換爲普通股，具體調整及需經股東批准。與此同時，Conduit 修改了與 Nirland Limited 現有的 265萬美元票據，使其允許以相同的匯率進行轉換。這兩張票據均需股東批准方可轉換，並可能導致最多 13300萬新普通股的發行。公司必須在規定的時間內爲新的票據提交轉售註冊聲明。如果在 2025 年 1 月...展開全部
Conduit Pharmaceuticals Inc. 向 A.G.P./Alliance Global Partners 發行了一張 5,737,500 美元的可轉換票據，到期日爲 2025 年 11 月 25 日。該票據按年利率 5.5% 計息，並可按每股 0.10 美元的價格轉換爲普通股，具體調整及需經股東批准。與此同時，Conduit 修改了與 Nirland Limited 現有的 265萬美元票據，使其允許以相同的匯率進行轉換。這兩張票據均需股東批准方可轉換，並可能導致最多 13300萬新普通股的發行。公司必須在規定的時間內爲新的票據提交轉售註冊聲明。如果在 2025 年 1 月 9 日之前未獲得 Nirland 票據轉換的股東批准，Conduit 將面臨每天 100,000 美元的罰款。這些票據是無擔保的，受紐約法律管轄，並根據 SEC 註冊要求的豁免發行。若需要修改註冊聲明，Conduit 可暫停使用招股說明書，累計最多 60 個交易日，限於 12 個月內。

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間